315 related articles for article (PubMed ID: 33813435)
21. Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.
Masuishi T; Taniguchi H; Kawakami T; Kawamoto Y; Kadowaki S; Onozawa Y; Muranaka T; Tajika M; Yasui H; Nakatsumi H; Yuki S; Muro K; Omae K; Komatsu Y; Yamazaki K
ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392174
[TBL] [Abstract][Full Text] [Related]
22. Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer.
Zaniboni A; Barone CA; Banzi MC; Bergamo F; Blasi L; Bordonaro R; Bartolomeo MD; Costanzo FD; Frassineti GL; Garufi C; Giuliani F; Latiano TP; Martinelli E; Personeni N; Racca P; Tamburini E; Tonini G; Besse MG; Spione M; Falcone A
Future Oncol; 2021 Jun; 17(18):2315-2324. PubMed ID: 33663264
[TBL] [Abstract][Full Text] [Related]
23. Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution.
Kotani D; Shitara K; Kawazoe A; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Doi T; Ohtsu A; Yoshino T
Clin Colorectal Cancer; 2016 Sep; 15(3):e109-15. PubMed ID: 26723516
[TBL] [Abstract][Full Text] [Related]
24. Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer.
Kasper S; Kisro J; Fuchs M; Müller C; Schulz-Abelius A; Karthaus M; Rafiyan MR; Stein A
BMC Cancer; 2018 Nov; 18(1):1124. PubMed ID: 30445951
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis.
Basso M; Signorelli C; Calegari MA; Lucchetti J; Zurlo IV; Dell'Aquila E; Arrivi G; Zoratto F; Santamaria F; Saltarelli R; Trovato G; Caira G; Angotti L; Schirripa M; Anghelone A; Schietroma F; Chilelli MG; Salvatore L; Pozzo C; Tortora G
Target Oncol; 2024 May; 19(3):371-382. PubMed ID: 38613732
[TBL] [Abstract][Full Text] [Related]
26. Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center.
Patel AK; Abhyankar R; Brais LK; Duh MS; Barghout VE; Huynh L; Yenikomshian MA; Ng K; Fuchs CS
Oncologist; 2021 Dec; 26(12):e2161-e2169. PubMed ID: 34406678
[TBL] [Abstract][Full Text] [Related]
27. Trifluridine/tipiracil in combination with local therapy may be a favorable option for refractory metastatic colorectal cancer patients: A case report.
Lin YL; Liu KL; Lin BR
Medicine (Baltimore); 2020 Oct; 99(43):e22780. PubMed ID: 33120790
[TBL] [Abstract][Full Text] [Related]
28. Improving survival in metastatic colorectal cancer through optimized patient selection.
Bekaii-Saab TS; Barzi A; Cusnir M
Clin Adv Hematol Oncol; 2024 Jun; 22 Suppl 4(5):1-20. PubMed ID: 38805297
[TBL] [Abstract][Full Text] [Related]
29. Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer.
Walter T; Hawkins NS; Pollock RF; Colaone F; Shergill S; Ross PJ
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2575-2587. PubMed ID: 32715436
[TBL] [Abstract][Full Text] [Related]
30. Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis.
Casadei-Gardini A; Vagheggini A; Gelsomino F; Spallanzani A; Ulivi P; Orsi G; Rovesti G; Andrikou K; Tamburini E; Scartozzi M; Cascinu S
Clin Colorectal Cancer; 2020 Jun; 19(2):82-90.e9. PubMed ID: 32192883
[TBL] [Abstract][Full Text] [Related]
31. Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program.
Cremolini C; Rossini D; Martinelli E; Pietrantonio F; Lonardi S; Noventa S; Tamburini E; Frassineti GL; Mosconi S; Nichetti F; Murgioni S; Troiani T; Borelli B; Zucchelli G; Dal Maso A; Sforza V; Masi G; Antoniotti C; Di Bartolomeo M; Miceli R; Ciardiello F; Falcone A
Oncologist; 2018 Oct; 23(10):1178-1187. PubMed ID: 29739893
[TBL] [Abstract][Full Text] [Related]
32. Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer.
Ishizaki T; Mazaki J; Enomoto M; Shigoka M; Kasahara K; Matsudo T; Kawakita H; Nagakawa Y; Katsumata K; Tsuchida A
Anticancer Res; 2021 Apr; 41(4):2157-2163. PubMed ID: 33813427
[TBL] [Abstract][Full Text] [Related]
33. Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab.
Matsumoto T; Ikoma T; Yamamura S; Miura K; Tsuduki T; Watanabe T; Nagai H; Takatani M; Yasui H
Sci Rep; 2023 Feb; 13(1):2433. PubMed ID: 36765099
[TBL] [Abstract][Full Text] [Related]
34. Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data.
Fernández Montes A; Carmona-Bayonas A; Jimenez-Fonseca P; Vázquez Rivera F; Martinez Lago N; Covela Rúa M; Cousillas Castiñeiras A; Gonzalez Villarroel P; De la Cámara Gómez J; Méndez JCM; Carriles Fernández C; Sanchez Cánovas M; Garcia García T
Sci Rep; 2021 Jul; 11(1):14321. PubMed ID: 34253805
[TBL] [Abstract][Full Text] [Related]
35. Dose-escalation strategy in refractory metastatic colorectal cancer: A change in terms of cost-effectiveness.
Giuliani J; Fiorica F; Ponturo G; Azzurro M; Ruzzenente A; Bonetti A
J Oncol Pharm Pract; 2021 Jun; 27(4):974-977. PubMed ID: 33541208
[TBL] [Abstract][Full Text] [Related]
36. Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme.
Iveson T; Carter AM; Shiu KK; Spooner C; Stevens D; Mullamitha S
BMC Cancer; 2020 Feb; 20(1):91. PubMed ID: 32013902
[TBL] [Abstract][Full Text] [Related]
37. Systematic Review and Meta-Analysis of Multitargeted Tyrosine Kinase Inhibitors in Patients With Intractable Metastatic Colorectal Cancer.
Gao Z; Cao C; Bao Y; Fan Y; Chen G; Fu P
Technol Cancer Res Treat; 2020; 19():1533033820943241. PubMed ID: 32914703
[TBL] [Abstract][Full Text] [Related]
38. Economic evaluation of trifluridine and tipiracil hydrochloride in the treatment of metastatic colorectal cancer in Greece.
Gourzoulidis G; Maniadakis N; Petrakis D; Souglakos J; Pentheroudakis G; Kourlaba G
J Comp Eff Res; 2019 Feb; 8(3):133-142. PubMed ID: 30547679
[TBL] [Abstract][Full Text] [Related]
39. The Efficacy and Safety of Trifluridine/Tipiracil Treatment for Elderly Patients With Metastatic Colorectal Cancer in a Real-world Setting.
Shibutani M; En W; Okazaki Y; Kashiwagi S; Fukuoka T; Iseki Y; Hirakawa K; Ohira M
Anticancer Res; 2021 Dec; 41(12):6211-6216. PubMed ID: 34848475
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of Chemotherapy Rechallenge Versus Regorafenib or Trifluridine/Tipiracil in Third-Line Setting of Metastatic Colorectal Cancer: A Multicenter Retrospective Comparative Study.
Bazarbashi S; Alkhatib R; Aseafan M; Tuleimat Y; Abdel-Aziz N; Mahrous M; Elsamany S; Elhassan T; Alghamdi M
JCO Glob Oncol; 2024 Mar; 10():e2300461. PubMed ID: 38484194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
